Improving the Immune Response to Nanoparticle-Based SARS-CoV-2 Vaccines
改善基于纳米颗粒的 SARS-CoV-2 疫苗的免疫反应
基本信息
- 批准号:10648704
- 负责人:
- 金额:$ 23.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAdjuvantAntibodiesAntibody FormationAntibody ResponseAntibody titer measurementAntigen PresentationAntigensBiological AssayBolus InfusionCOVID-19 pandemicCOVID-19 vaccineCellsCommunicable DiseasesCoronavirusEncapsulatedEpitopesExposure toFormulationHealthHistologicHumanHydrogelsImmuneImmune responseImmunityImmunizationIn VitroIndividualInfluenzaInjectionsKineticsLibrariesMalignant NeoplasmsMeasuresMediatingMusNaturePhysiologicalPolymersPreventive vaccineProtein ArrayProtein EngineeringProteinsSARS-CoV-2 variantSecondary ImmunizationSerumSiteSurfaceSystemT cell responseT-LymphocyteTemperatureTestingTimeTransition TemperatureVaccinationVaccine DesignVaccinesVariantViralVirusWorkbiodegradable polymercontrolled releasecross reactivitycytokinedesignefficacy evaluationemerging pathogenimprovedin vivoin vivo imaging systemnanolabelnanoparticlenanovaccineneutralizing antibodypandemic diseaseparticlepathogenreceptorreceptor bindingresponsesynergismvaccine deliveryvaccine developmentvaccine effectivenessvaccine formulationvaccine strategy
项目摘要
PROJECT SUMMARY / ABSTRACT
Vaccines have been very effective at protecting against infectious diseases that pose
serious threats to human health. However, prophylactic vaccines can also be limited, particularly
if antigenic drift occurs to create variants of the pathogen; this can result in vaccines losing
potency over time, needing boosters to confer protection, and lower neutralization efficacy on
emerging viral variants – consequences which are observed in the current COVID-19 pandemic.
Recent studies have shown that the release kinetics of vaccines can be important in establishing
lasting and efficacious immunity. In particular, extending the exposure to antigens can result in
higher antibody titers and increased diversity of neutralizing antibodies that target a more diverse
set of epitopes, relative to immune responses from conventional bolus vaccination. Furthermore,
vaccines made from protein-based nanoparticles can elicit increased antibody production,
broader antigen cross-reactivity, and a more balanced Th1/Th2 response. This study tests the
hypothesis that the synergy in combining the effects of nanoparticle vaccines for effective antigen
presentation, together with a slower release to give a longer exposure to the vaccine, will elicit
increased durability of the immune response and a broader cross-reactivity for emerging viral
variants.
To test this hypothesis, we propose to encapsulate protein nanoparticle vaccines with a
biodegradable PLGA-PEG-PLGA (PPP)-based polymer to modulate the kinetics of its release
from an in vivo vaccine depot. This extended-release vaccine strategy will then be applied
towards SARS-CoV-2. We will evaluate the durability of the proposed vaccine strategy’s potency
and the breadth of cross-reactive immune responses toward the variants of SARS-CoV-2 and
other types of coronaviruses. Our specific aims are to: (1) create controlled-release nanoparticle
depot vaccines against SARS-CoV-2, and (2) determine the efficacy and immunological
responses to these vaccine nanoparticles that are encapsulated by the polymeric depot. Because
the design of these vaccines is modular and different antigens can be exchanged in a relatively
straightforward approach, the successful implementation of this proposed strategy for coronavirus
antigens could have broader applicability towards the development of vaccines for other infectious
pathogens.
项目摘要/摘要
疫苗在预防引起传染病方面一直非常有效。
对人类健康的严重威胁。然而,预防性疫苗也可能是有限的,尤其是
如果发生抗原漂移,产生病原体的变种;这可能导致疫苗丢失
效力随着时间的推移,需要助推器来提供保护,并降低中和效率
新出现的病毒变异--在当前的新冠肺炎大流行中观察到的后果。
最近的研究表明,疫苗的释放动力学在建立
持久有效的免疫力。特别是,延长接触抗原的时间可能会导致
更高的抗体效价和针对更多样化的中和抗体的多样性
相对于常规团注疫苗的免疫反应的一组表位。此外,
由基于蛋白质的纳米颗粒制成的疫苗可以诱导更多的抗体产生,
更广泛的抗原交叉反应,以及更平衡的Th1/Th2反应。这项研究测试了
假设在结合有效抗原的纳米颗粒疫苗的效果时的协同作用
展示,加上较慢的释放,使更长时间接触疫苗,将引发
提高免疫反应的持久性和对新出现的病毒的更广泛的交叉反应
变种。
为了验证这一假设,我们建议将蛋白质纳米颗粒疫苗包裹在
可生物降解PLGA-PEG-PLGA(PPP)聚合物对其释药动力学的调控
来自体内的疫苗仓库。然后将应用这种缓释疫苗策略
走向SARS-CoV-2。我们将评估拟议的疫苗策略的效力的持久性
对SARS-CoV-2和SARS-CoV-2变种的交叉反应免疫反应的广度
其他类型的冠状病毒。我们的具体目标是:(1)创造可控释纳米粒
SARS-CoV-2疫苗仓库,以及(2)确定疫苗的效力和免疫学
对聚合物库包裹的这些疫苗纳米颗粒的反应。因为
这些疫苗的设计是模块化的,不同的抗原可以在相对较短的时间内交换
直截了当的方法,成功实施这一拟议的冠状病毒战略
抗原可在开发其他传染性疾病疫苗方面具有更广泛的适用性。
病原体。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Szu-Wen Wang其他文献
Szu-Wen Wang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Szu-Wen Wang', 18)}}的其他基金
Tumor-Associated Antigen Delivery using Protein Nanoparticles for Combined Immunotherapy
使用蛋白质纳米颗粒进行肿瘤相关抗原递送以进行联合免疫治疗
- 批准号:
10319541 - 财政年份:2019
- 资助金额:
$ 23.55万 - 项目类别:
Tumor-Associated Antigen Delivery using Protein Nanoparticles for Combined Immunotherapy
使用蛋白质纳米颗粒进行肿瘤相关抗原递送以进行联合免疫治疗
- 批准号:
9886249 - 财政年份:2019
- 资助金额:
$ 23.55万 - 项目类别:
Tumor-Associated Antigen Delivery using Protein Nanoparticles for Combined Immunotherapy
使用蛋白质纳米颗粒进行肿瘤相关抗原递送以进行联合免疫治疗
- 批准号:
10063869 - 财政年份:2019
- 资助金额:
$ 23.55万 - 项目类别:
Nanoparticle-Modulated Response Against Tumor-Associated Antigens
纳米颗粒调节针对肿瘤相关抗原的反应
- 批准号:
8824191 - 财政年份:2014
- 资助金额:
$ 23.55万 - 项目类别:
Multifunctional Protein Nanocapsules for Targeted Delivery
用于靶向递送的多功能蛋白质纳米胶囊
- 批准号:
8019564 - 财政年份:2010
- 资助金额:
$ 23.55万 - 项目类别:
Multifunctional Protein Nanocapsules for Targeted Delivery
用于靶向递送的多功能蛋白质纳米胶囊
- 批准号:
7772901 - 财政年份:2010
- 资助金额:
$ 23.55万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 23.55万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 23.55万 - 项目类别:
Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 23.55万 - 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 23.55万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 23.55万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 23.55万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 23.55万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 23.55万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 23.55万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 23.55万 - 项目类别: